MRK vs ORCL: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and Oracle Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-18.
Merck & Co., Inc. · Healthcare
$121.42
-2.9% upside to fair value
Med Conviction
Grade B
VS
Oracle Corporation · Technology
$175.08
+24.7% upside to fair value
Grade B
QuantHub Verdict
ORCL has more upside to fair value
(+24.7%).
MRK trades at a lower forward P/E
(14.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
ORCL |
| Current Price |
$121.42 |
$175.08 |
| Fair Value Estimate |
$118.00 |
$218.26 |
| Upside to Fair Value |
-2.9%
|
+24.7%
|
| Market Cap |
$300.2B |
$503.5B |
| Forward P/E |
14.0x
|
30.8x
|
| EV / EBITDA |
11.8x
|
21.4x
|
| Price / Sales |
4.1x
|
7.9x
|
| Price / FCF |
21.4x
|
-20.4x
|
| Revenue Growth YoY |
+1.3%
|
+7.0%
|
| Gross Margin |
81.5%
|
66.4%
|
| Operating Margin |
41.2%
|
30.8%
|
| Return on Equity |
34.7%
|
57.4%
|
| Dividend Yield |
3.1% |
0% |
| FCF Yield |
4.7%
|
—
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Merck is a top-5 global pharmaceutical company generating $65B in annual revenue with 81.5% gross margins and 28% net margins. Keytruda, the world's best-selling drug at $31.7B (49% of pharma revenue), faces patent expiry in 2028. Merck is aggressively building replacements through M&A and pipeline launches: Winrevair ($1.4B year one), Capvaxive ($759M), and the $6.7B Terns acquisition for TERN-7…
Oracle Corporation is a leading technology company specializing in software infrastructure, with a dominant Cloud and License Business segment generating 85.8% of its $57.4 billion revenue in fiscal 2025. The company benefits from a durable competitive moat driven by decades of leadership continuity, aggressive M&A history, and a strong position in enterprise software and cloud services. Despite …
Accumulation Zones
| Metric |
MRK |
ORCL |
| Zone Low |
$88.00 |
$163.69 |
| Zone High |
$100.00 |
$185.52 |
| In Buy Zone? |
No
|
Yes
|